Australia’s healthcare manufacturing push is gaining momentum, with a number of ASX companies taking products to the world. .

I look at three healthcare businesses that could be much larger companies in the years ahead. The post The hunt for Australia ...

April 23 (Reuters) - Australian biotech giant CSL ⁠extended ⁠losses on Thursday, lingering near decade ⁠lows, after the U.S. military scrapped its flu vaccine mandate, dealing another blow to the ...

The biotech’s rough 18 months is nothing compared to what happened 20 years ago, with the chairman saying that he’ll finish ...

(Reuters) -Australian biotech CSL on Tuesday delayed its planned vaccine division spin-off and cut earnings forecasts due to a bigger-than-expected decline in U.S. flu vaccination rates, sending its ...

Australia's CSL on Monday named interim chief Gordon Naylor as chair from March next ​year, the latest leadership shake-up days after naming GSK executive ​Deborah Waterhourse as its first female CEO.

Yesterday, CSL named Deborah Waterhouse as its next CEO. Should investors now pick CSL over BHP? The post CSL vs BHP shares: ...

(Reuters) - Shares of CSL Ltd fell more than 3% on Tuesday after the Australian biotech firm forecast an annual profit that was higher than a year earlier but below market consensus. The company ...

Waterhouse is due to take the helm of CSL on 1st February next year, around a year after Paul McKenzie abruptly departed the company after only a brief tenure as CEO, to be replaced on an interim ...

The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed Deborah Waterhouse as Chief Executive Officer and Managing Director of CSL from 1 February 2027. The ...

ViiV Healthcare has announced that Deborah Waterhouse is stepping down as chief executive officer of ViiV Healthcare and president of GSK Global Health to join CSL as chief execut ...